Skip to main content
SpringerLink
Log in

ADJUBIL

Immuntherapie mit Durvalumab und Tremelimumab in Kombination mit oder ohne Capecitabin im adjuvanten Setting für maligne biliäre Tumoren – eine Phase-II-Studie

ADJUBIL

Immunotherapy with durvalumab and tremelimumab in combination with or without capecitabin in the adjuvant setting for malignant biliary tumors—a phase II trial

  • Sektion B - Klinische Studien
  • Published:
Forum Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Weiterführende Literatur

  1. Goetze TO, Paolucci V (2008) Immediate re-resection of T1 incidental gallbladder carcinomas: a survival analysis of the German registry. Surg Endosc 22(11):2462–2465

    Article  CAS  Google Scholar 

  2. Goetze TO, Bechstein WO, Bankstahl US et al (2020) Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC)—a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)—the AIO/CALGP/ACO-GAIN-trial. BMC Cancer 20(1):122

    Article  CAS  Google Scholar 

  3. Lammert F, Neubrand MW, Bittner R, Feussner H, Greiner L, Hagenmüller F et al (2007) S3-guidelines for diagnosis and treatment of gallstones. German Society for Digestive and Metabolic Diseases and German Society for Surgery of the Alimentary Tract. Z Gastroenterol 45(9):971–1001

    Article  CAS  Google Scholar 

  4. Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 20(5):663–673

    Article  CAS  Google Scholar 

  5. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H et al (2002) Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95(8):1685–1695

    Article  Google Scholar 

  6. Weber SM, Ribero D, O’Reilly EM et al (2015) Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford) 17(8):669–680

    Article  Google Scholar 

  7. NCCN (2019) Guidelines for hepatobiliary cancers. Version 3

    Google Scholar 

  8. Bridgewater J, Galle PR, Khan SA et al (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60(6):1268–1289

    Article  Google Scholar 

  9. Ebata T, Hirano S, Konishi M et al (2018) Bile Duct Cancer Adjuvant Trial (BCAT) study group. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg 105:192–202

    Article  CAS  Google Scholar 

  10. Edeline J, Benabdelghani M, Bertaut A et al (2019) Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol 37:658–667

    Article  CAS  Google Scholar 

  11. Götze TO (2021) Gallengangskarzinome: Heterogene Gruppe maligner biliärer Tumoren. J Onkol 4/2021

  12. Valle JW, Borbath I, Khan SA et al (2016) Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):v28–v37

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Klinisch-Onkologische Forschung (IKF), Krankenhaus Nordwest gGmbH, Steinbacher Hohl 2–26, 60488, Frankfurt, Deutschland

    Thorsten O. Götze & Salah-Eddin Al-Batran

  2. Institut für Klinische Krebsforschung IKF GmbH, Krankenhaus Nordwest, Frankfurt, Deutschland

    Lisa Kochen

Authors
  1. Thorsten O. Götze
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa Kochen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Salah-Eddin Al-Batran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thorsten O. Götze.

Ethics declarations

Interessenkonflikt

T.O. Götze, L. Kochen und S.-E. Al-Batran geben an, dass kein Interessenkonflikt besteht.

Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Götze, T.O., Kochen, L. & Al-Batran, SE. ADJUBIL. Forum 36, 414–416 (2021). https://doi.org/10.1007/s12312-021-00971-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12312-021-00971-8

Search

Navigation